Free Trial
NASDAQ:SNTI

Senti Biosciences Q3 2023 Earnings Report

Senti Biosciences logo
$1.78 +0.05 (+2.89%)
Closing price 10/8/2025 04:00 PM Eastern
Extended Trading
$1.79 +0.01 (+0.56%)
As of 10/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Senti Biosciences EPS Results

Actual EPS
-$2.50
Consensus EPS
-$4.80
Beat/Miss
Beat by +$2.30
One Year Ago EPS
N/A

Senti Biosciences Revenue Results

Actual Revenue
$0.34 million
Expected Revenue
$0.94 million
Beat/Miss
Missed by -$600.00 thousand
YoY Revenue Growth
N/A

Senti Biosciences Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Monday, November 13, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Senti Biosciences' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Senti Biosciences Earnings Headlines

Senti Bio to Present at BioJapan
Arizona-made nanochips the new millionaire maker?
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.tc pixel
See More Senti Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Senti Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Senti Biosciences and other key companies, straight to your email.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release. These platforms support a diverse pipeline of preclinical cell therapy programs targeting solid tumors, hematologic malignancies and autoimmune disorders.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Senti Biosciences completed its initial public offering in June 2021 and is listed on the Nasdaq exchange. The company collaborates with academic and industry partners to advance its research and expand its proprietary platform capabilities.

Senti is led by a management team combining expertise in synthetic biology, immunology and biotechnology development. The leadership team includes seasoned industry executives and academic scientists committed to translating circuit-based cell therapies into clinical applications worldwide.

View Senti Biosciences Profile

More Earnings Resources from MarketBeat